News

In a study released today in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer’s drug “galantamine” cut key markers of inflammation – a hallmark of metabolic

IBM scientists and the University of Alberta in Edmonton, Canada, have published new data in Nature's partner journal. The research was on computational psychiatry which uses AI to

The FDA approval marks the first subcutaneous self-injection treatment option for patients with SLE, the most common form of lupus – a chronic, incurable autoimmune disease producing autoantibodies

The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel, potent, and selective JAK1 inhibitor, in combination with corticosteroids compared to placebo plus corticosteroids in patients

LUSDUNA Nexvue is being developed by Merck with funding from Samsung Bioepis. With the tentative approval, LUSDUNA Nexvue has met all required regulatory standards for follow-on biologics of

The approval allows to market Kyntheum in all 28 European Union (EU) member countries, as well as Iceland, Liechtenstein and Norway. Kyntheum is a new biologic medicine developed

Top line data from this trial, being conducted in Italy, Israel, Greece and Turkey, is expected in Q4 2018. The primary objective of this multi-centre, multi-country and dose-ranging

These are the first data to demonstrate the potential to treat the underlying cause of CF in these patients, who have a severe and difficult-to-treat type of the

Dharmacon, which manufactures RNAi products, has a portfolio of gene editing products, particularly in CRISPR reagents and arrayed libraries. It had generated revenues of $36.7m in 2016 with an EBITDA of $5.4m.